The Impact of Alemtuzumab and Basiliximab Induction on Patient Survival and Time to Bronchiolitis Obliterans Syndrome in Double Lung Transplantation Recipients. Issue 8 (23rd May 2016)

• Record Type: Journal Article
• Authors: Furuya, Y.; Jayarajan, S. N.; Taghavi, S.; Cordova, F. C.; Patel, N.; Shiose, A.; Leotta, E.; Criner, G. J.; Guy, T. S.; Wheatley, G. H.; Kaiser, L. R.; Toyoda, Y.
• Is Part Of: American journal of transplantation. Volume 16:Issue 8(2016:Aug.)
• Page Start: 2334
• Page End: 2341
• Publication Date: 2016-05-23
• Subjects: clinical research/practice -- health services and outcomes research -- immunosuppression/immune modulation -- lung transplantation/pulmonology -- immunosuppressant -- fusion proteins and monoclonal antibodies: alemtuzumab -- immunosuppressant -- fusion proteins and monoclonal antibodies: basiliximab/daclizumab -- immunosuppressive regimens -- induction -- lung (allograft) function/dysfunction -- bronchiolitis obliterans (BOS); Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ajt.13739
• Languages: English
• ISSNs: 1600-6135

Abstract

Abstract : We examined the effect of alemtuzumab and basiliximab induction therapy on patient survival and freedom from bronchiolitis obliterans syndrome (BOS) in double lung transplantation. The United Network for Organ Sharing database was reviewed for adult double lung transplant recipients from 2006 to 2013. The primary outcome was risk‐adjusted all‐cause mortality. Secondary outcomes included time to BOS. There were 6117 patients were identified, of whom 738 received alemtuzumab, 2804 received basiliximab, and 2575 received no induction. Alemtuzumab recipients had higher lung allocation scores compared with basiliximab and no‐induction recipients (41.4 versus 37.9 versus 40.7, p < 0.001) and were more likely to require mechanical ventilation before to transplantation (21.7% versus 6.5% versus 6.2%, p < 0.001). Median survival was longer for alemtuzumab and basiliximab recipients compared with patients who received no induction (2321 versus 2352 versus 1967 days, p = 0.001). Alemtuzumab (hazard ratio 0.80, 95% confidence interval 0.67–0.95, p = 0.009) and basiliximab induction (0.88, 0.80–0.98, p = 0.015) were independently associated with survival on multivariate analysis. At 5 years, alemtuzumab recipients had a lower incidence of BOS (22.7% versus 55.4 versus 55.9%), and its use was independently associated with lower risk of developing BOS on multivariate analysis. While both induction therapies were associated with improved survival, patients who received alemtuzumab had greater median freedom from BOS. Abstract : While the use of either alemtuzumab or basiliximab induction confer a survival benefit over no induction therapy, the use of alemtuzumab prolongs time to bronchiolitis obliterans syndrome in double lung transplant recipients. Corris's editorial is onpage 2250 .